Year: 2023
Type: review
Abstract: Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs that antagonize the CGRPergic system. Therefore, this review focuses on summarizing the general pharmacology of the different types of treatments currently available, which target directly or indirectly the CGRP receptor or its ligand. Moreover, the latest evidence regarding the selectivity and site of action of CGRP small molecule antagonists (gepants) and monoclonal antibodies is critically discussed. Finally, the reasons behind non-responders to anti-CGRP drugs and rationale for combining and/or switching between these therapies are addressed.
Source: The Journal of Headache and Pain
Institutions: King's College London, Universitat Autònoma de Barcelona, Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Université de Toulouse, University of Oxford, Vilnius University, Nicolae Testemițanu State University of Medicine and Pharmacy, University of Tehran, Tehran University of Medical Sciences, Riga East University Hospital, Beth Israel Deaconess Medical Center, Harvard University, South London and Maudsley NHS Foundation Trust, King's College Hospital, Wellcome Trust
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,490
Funder: International Headache Society
OpenAlex ID: W4386583001
